Literature DB >> 15752920

The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?

David M Kendall1.   

Abstract

CVD is the primary cause of morbidity and mortality in patients who have diabetes mellitus. Most such patients have at least one lipid abnormality. Managing these complex lipid disorders is a crucial component of comprehensive diabetes mellitus care and limits the risk for cardiovascular morbidity and mortality. With the high prevalence of mixed lipid disorders, management must focus on all components of the lipid profile. Lowering LDL-C levels remains the first priority, but abnormalities in HDL-C and TG levels also should be treated aggressively. Statins, fibrates, and niacin, along with newer therapies such as ezetimibe, can improve significantly components of the lipid profile. Alone or in combination, these agents can treat the dyslipidemia of diabetes mellitus effectively and safely.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15752920     DOI: 10.1016/j.ecl.2004.11.004

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  8 in total

1.  Abnormal cholesterol is associated with prefrontal white matter abnormalities among obese adults, a diffusion tensor imaging study.

Authors:  Jessica I Cohen; Fanny Cazettes; Antonio Convit
Journal:  Neuroradiol J       Date:  2011-11-15

2.  Aerobic Exercise Prevents Insulin Resistance Through the Regulation of miR-492/Resistin Axis in Aortic Endothelium.

Authors:  Ying Cai; Kang-Ling Xie; Fan Zheng; Sui-Xin Liu
Journal:  J Cardiovasc Transl Res       Date:  2018-09-19       Impact factor: 4.132

Review 3.  Metformin use among individuals at risk for type 2 diabetes.

Authors:  Lewis H Kuller
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

4.  Evaluation of the value of conventional and unconventional lipid parameters for predicting the risk of diabetes in a non-diabetic population.

Authors:  Guotai Sheng; Maobin Kuang; Ruijuan Yang; Yanjia Zhong; Shuhua Zhang; Yang Zou
Journal:  J Transl Med       Date:  2022-06-11       Impact factor: 8.440

5.  Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

Authors:  M Bajaj; S Suraamornkul; L J Hardies; L Glass; N Musi; R A DeFronzo
Journal:  Diabetologia       Date:  2007-05-23       Impact factor: 10.122

6.  Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.

Authors:  Robert S Rosenson; Dawn M Carlson; Maureen T Kelly; Carolyn M Setze; Boaz Hirshberg; James C Stolzenbach; Laura A Williams
Journal:  Cardiovasc Drugs Ther       Date:  2011-02       Impact factor: 3.727

7.  Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility.

Authors:  Jing Li; Qian Wang; Weidong Chai; Mei-Hua Chen; Zhenqi Liu; Weibin Shi
Journal:  Cardiovasc Diabetol       Date:  2011-12-28       Impact factor: 9.951

8.  A replication study of GWAS-derived lipid genes in Asian Indians: the chromosomal region 11q23.3 harbors loci contributing to triglycerides.

Authors:  Timothy R Braun; Latonya F Been; Akhil Singhal; Jacob Worsham; Sarju Ralhan; Gurpreet S Wander; John C Chambers; Jaspal S Kooner; Christopher E Aston; Dharambir K Sanghera
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.